Salvage boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: Evaluation of 34 cases in Taiwan

Yi Wei Chen, Yi Yen Lee, Chun Fu Lin, Po Shen Pan, Jen Kun Chen, Chun Wei Wang, Shih Ming Hsu, Yu Cheng Kuo, Tien Li Lan, Sanford P.C. Hsu, Muh Lii Liang, Robert Hsin Hung Chen, Feng Chi Chang, Chih Chun Wu, Shih Chieh Lin, Hsiang Kuang Liang, Jia Cheng Lee, Shih Kuan Chen, Hong Ming Liu, Jinn Jer PeirKo Han Lin, Wen Sheng Huang, Kuan Hsuan Chen, Yu Mei Kang, Shueh Chun Liou, Chun Chieh Wang, Ping Ching Pai, Chih Wei Li, Daniel Quah Song Chiek, Tai Tong Wong, Shih Hwa Chiou, Yee Chao, Hiroki Tanaka, Fong In Chou, Koji Ono

研究成果: 雜誌貢獻文章同行評審

4 引文 斯高帕斯(Scopus)

摘要

Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan–Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival.

原文英語
文章編號334
期刊Biology
10
發行號4
DOIs
出版狀態已發佈 - 2021

ASJC Scopus subject areas

  • 生物化學、遺傳與分子生物學 (全部)
  • 免疫學與微生物學 (全部)
  • 農業與生物科學 (全部)

指紋

深入研究「Salvage boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: Evaluation of 34 cases in Taiwan」主題。共同形成了獨特的指紋。

引用此